Philip Sell is the co-founder and CEO of Metaba, a company leveraging metabolomics to advance both precision diagnostics and therapeutic development. Metaba’s AI-driven platform identifies biomarkers for drug discovery, clinical diagnostics, and disease treatment, streamlining data interpretation to accelerate research and improve patient outcomes. In addition to its metabolomics-driven insights, Metaba is developing novel therapeutics targeting infectious diseases, including drug-resistant tuberculosis. Through a combination of multiomics integration and innovative drug development, Metaba is transforming how diseases are diagnosed and treated. Metaba was co-founded by Joe Lee.